Skip to Navigation Skip to Search Skip to Content
Search All Centers

What Is High-Risk CLL?

Read Transcript Download/Print Transcript

Published on March 6, 2018

What characteristics of chronic lymphocytic leukemia (CLL) are considered high-risk? Will traditional treatment methods still work? CLL expert Dr. Jeff Sharman from The US Oncology Network describes what disease features will distinguish a high-risk condition and the latest technology available for a CLL treatment strategy. Watch now to learn more.

Provided by CLL Global Research Foundation, which received support from AbbVie Inc., Gilead Sciences, TG Therapeutics, Pharmacyclics LLC and Janssen Biotech, Inc., and Genentech. Produced by Patient Power in collaboration with The US Oncology Network, Compass Oncology, and Willamette Valley Cancer Institute and Research Center.

Featuring

Partners

CLL Global Research Foundation Compass Oncology The US Oncology Network Willamette Valley Cancer Institute and Research Center

You might also like

Transcript | What Is High-Risk CLL?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Dr. Sharman, what is high-risk CLL, and are there advances for it?

Dr. Sharman:   

I think a lot of the advances are really even more dramatic amongst patients with high-risk CLL. What is high-risk CLL? There's, I wouldn’t say that there's one uniform definition of high-risk CLL for every circumstance, but there are certain things we put into that bucket. Patients with 17P deletion or P53 mutations, that is concerns us that our traditional chemo-immunotherapy approaches aren’t going to be particularly good. They don’t last very long. Short remissions. Patients who relapse very early after a prior chemo-immunotherapy regimen, also a potential high-risk group.

I think now as the field is shifting more towards these targeted agents. We are looking at looking at 17P and its impact on patients treated with ibrutinib (Imbruvica), and it does look like patients with 17P may not get as good a benefit as the patients without 17P. However, they still do better on ibrutinib than anything previously. I think that this is a shifting field right now and what was high-risk just a short while ago may be different than what’s high-risk in the near term. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.